Authors

Latest:

Long-Term Safety and Efficacy of Selinexor Maintenance Treatment in Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

Dr. Debra Richardson presents a subgroup analysis of the SIENDO trial, showing that selinexor maintenance therapy significantly improves progression-free survival and delays subsequent treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer, with manageable safety and potential long-term benefit.

Monica M. Mita, MD

Latest:

Dr. Mita on Treatment Selection in ER+, HER2- Breast Cancer

Monica M. Mita, MD, discusses treatment selection for patients with estrogen receptor–positive, HER2-negative breast cancer.

Sanjay Popat, BSc, MBBS, FRCP, PhD

Latest:

Dr Popat on the Efficacy and Safety Profiles of Zongertinib in HER2-Mutated NSCLC

Sanjay Popat, BSc, MBBS, FRCP, PhD, discusses data that have been reported with zongertinib in patients with HER2-mutated NSCLC.

Jin Qian, PhD

Latest:

Dr Qian on Preclinical Data for a CXCR4 Partial Agonist Plus Anti–PD-1 Therapy in Gastric Cancer.

Jin Qian, PhD, discusses preclinical findings for CXCR4 partial agonist in combination with anti–PD-1 therapy in advanced gastric cancer.

Suchita Pakkala, MD

Latest:

Dr. Pakkala on Integrating Local Therapy into HER2+ Breast Cancer Treatment

Suchita Pakkala, MD, discusses ongoing efforts to integrate local therapy into HER2-positive breast cancer treatment.

Katherine Clifton, MD

Latest:

Insights From SABCS 2024 and Future Directions in Breast Cancer

Dr. Gandhi and Dr. Clifton explore clinical decision-making and sequencing for selective estrogen receptor degraders (SERDs), antibody-drug conjugates (ADCs), and other targeted therapies in hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), balancing efficacy, safety, and patient characteristics, while highlighting promising data from the 2024 San Antonio Breast Cancer Symposium (SABCS) and the role of precision medicine in improving outcomes and patient experiences.

Sapna Patel, BA, MD

Sapna Patel, MD, is a professor in the Division of Medical Oncology, the leader of the Cutaneous Oncology Program, and the William Robinson Endowed Chair in Cancer Research at the University of Colorado Cancer Center.

Latest:

RP1: An Emerging Intratumoral Therapy

Panelists discuss the promising systemic responses of RP1, an oncolytic virus therapy for melanoma, emphasizing its expanded applicability through visceral tumor injection and the need for further data to optimize dosing strategies and confirm durability compared with other treatments.

Jathin Bandari, MD

Latest:

ASCO GU 2022: Piecing Together Prostate Cancer Data With Drs. Tanya Dorff and Jathin Bandari

OncLive speaks with Drs. Tanya Dorff and Jathin Bandari on some exciting prostate cancer studies.

Hadeel Assad, MD

Hadeel Assad, MD, is an associate professor, clinician educator, and medical oncologist at Wayne State University and Karmanos Cancer Institute

Latest:

The Move From Blood to Solid: Open Opportunities for CAR T-Cell Therapy in Solid Tumors

There remains a significant unmet need for better treatments that prolong life and preserve the quality of life in women with metastatic breast cancer.

Fortunato Ciardiello, MD, PhD, University of Campania

Latest:

Optimizing Treatment Strategies in Relapsed/Refractory Metastatic CRC

Josh Ruess, MD 

Latest:

Closing Perspectives: Unmet Needs, Emerging Advances, and the Future of Early-Stage NSCLC Treatment

Panelists discuss how future advances will focus on biomarker-driven personalized approaches, platform trials to increase pathologic complete response rates, circulating tumor DNA (ctDNA)-guided therapy escalation and de-escalation, and the critical importance of comprehensive molecular testing in the neoadjuvant setting.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS

Latest:

Dr Sherman on Advances in Surgical Brain Tumor Management

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.

Tisch Cancer Institute

Latest:

Mount Sinai Researchers Discover How Early-Stage Breast Cancer Can Become a Silent Killer in Some Patients

Mount Sinai researchers have discovered a previously unknown mechanism in which not-yet-malignant cells from early breast cancer tumors travel to other organs and, eventually, “turn on” and become metastatic breast cancer.

Eric A. Singer, MD

Latest:

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

UCSF Helen Diller Family Comprehensive Cancer Center

Latest:

Novel Immunotherapy Combination Destroys Colorectal Liver Metastases

Researchers from UCSF discovered that a combination of immunotherapies can reprogram the immune environment of colon cancer tumors in the liver.

Jin-Ji Yang, MD

Jin-Ji Yang, MD is an oncologist at Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital, at the Guangdong Academy of Medical Sciences at the Southern Medical University.

Latest:

Dr Yang on Osimertinib Plus Savolitinib in MET-Aberrant, EGFR-Mutant Advanced NSCLC

Jin-Ji Yang, MD, discusses osimertinib plus savolitinib as a first-line treatment in patients with de novo MET-aberrant, EGFR-mutant advanced NSCLC.

Phulong L. Mai, MD

Latest:

Dr. Mai on Barriers of Genetic Testing in CRC

Phuong L. Mai, MD, discusses barriers of genetic testing in colorectal cancer.

Meriem Mokhtech, MD

Latest:

Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

John Crown, BCh, BAO, BSc, MD, MBA

Latest:

Dr. Crown on the Investigation of Lapatinib Plus Chemotherapy in HER2+ Breast Cancer

John Crown, MB, BCh, BAO, BSc, MD, MBA, discusses the rationale for evaluating lapatinib (Tykerb) with standard trastuzumab/chemotherapy regimen in patients with HER2-positive breast cancer, as well as contextualizes results from a phase 2 trial.

Susan E. Waltz, PhD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.